Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478592 | 0.85 | CDK1 (0.50) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL28476418 | 0.80 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL2179785 | 0.78 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL107915 | 0.78 | PDPK1 (0.40) | — | |
| SCHEMBL5507965 | 0.76 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBCDK1 | |
| SCHEMBL7063134 | 0.74 | PDPK1 (0.37) | CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL667795 | 0.72 | PNP (0.61) | — | |
| SCHEMBL6888654 | 0.72 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2576515 | 0.72 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL3453941 | 0.72 | PI4KA (0.54) | PI4KAPI4K2BPI4K2API4KBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449207-B2 | Acyclic nucleoside phosphonate diesters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180360859-A1 | Acyclic Nucleoside Phosphonate Diesters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-12-20 | — | — | US | disclosed |
| US-10076532-B2 | Acyclic nucleoside phosphonate diesters | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-18 | — | — | US | disclosed |
| US-20170304330-A1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1628685-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PI4KA 51/4885PI4K2B 112/4885PI4K2A 84/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PI4KA 51/4885PI4K2B 112/4885PI4K2A 84/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PI4KA 51/4885PI4K2B 112/4885PI4K2A 84/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | PI4KA 51/4885PI4K2B 112/4885PI4K2A 84/4885 |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | PI4KA 27/4885PI4K2B 39/4885PI4K2A 34/4885 |
| US-20180360859-A1 | Acyclic Nucleoside Phosphonate Diesters | NTPCR, PNP, TYMP | PI4KA 167/4885PI4K2B 377/4885PI4K2A 305/4885 |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | PIK3CA, PHOSPHO1, PTEN | PI4KA 32/4885PI4K2B 44/4885PI4K2A 45/4885 |
| US-10449207-B2 | Acyclic nucleoside phosphonate diesters | NTPCR, PNP, TYMP | PI4KA 167/4885PI4K2B 377/4885PI4K2A 305/4885 |
| US-10076532-B2 | Acyclic nucleoside phosphonate diesters | NTPCR, PNP, TYMP | PI4KA 167/4885PI4K2B 377/4885PI4K2A 305/4885 |
| US-20170304330-A1 | ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS | NTPCR, PNP, TYMP | PI4KA 167/4885PI4K2B 377/4885PI4K2A 305/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | PI4KA 32/4885PI4K2B 44/4885PI4K2A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.